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Dimerisation
RolipramPDE4 family cAMP phosphodiesterases play a pivotal role in determining compartmentalised cAMP signalling
through targeted cAMP breakdown. Expressing the widely found PDE4D5 isoform, as both bait and prey in a
yeast 2-hybrid system, we demonstrated interaction consistent with the notion that long PDE4 isoforms form
dimers. Four potential dimerization sites were uncovered using a scanning peptide array approach, where a
recombinant puriﬁed PDE4D5 fusion protein was used to probe a 25-mer library of overlapping peptides
covering the entire PDE4D5 sequence. Key residues involved in PDE4D5 dimerization were deﬁned using a
site-directed mutagenesis programme directed by an alanine scanning peptide array approach. Critical residues
stabilising PDE4D5 dimerization were deﬁned within the regulatory UCR1 region found in long, but not short,
PDE4 isoforms, namely the Arg173, Asn174 and Asn175 (DD1) cluster. Disruption of the DD1 cluster was not
sufﬁcient, in itself, to destabilise PDE4D5 homodimers. Instead, disruption of an additional interface, located on
the PDE4 catalytic unit, was also required to convert PDE4D5 into a monomeric form. This second dimerization
site on the conserved PDE4 catalytic unit is dependent upon a critical ion pair interaction. This involves Asp463
and Arg499 in PDE4D5, which interact in a trans fashion involving the two PDE4D5 molecules participating in
the homodimer. PDE4 long isoforms adopt a dimeric state in living cells that is underpinned by two key
contributory interactions, one involving the UCRmodules and one involving an interface on the core catalytic do-
main. We propose that short forms do not adopt a dimeric conﬁguration because, in the absence of the UCR1
module, residual engagement of the remaining core catalytic domain interface provides insufﬁcient free energy
to drive dimerization. The functioning of PDE4 long and short forms is thus poised to be inherently distinct due to
this difference in quaternary structure.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Cyclic AMP is a ubiquitous secondmessenger that plays a pivotal role
in regulating many key cellular processes [1–5]. cAMP signalling in
mammalian cells is compartmentalised so that spatially distinct sub-
populations of the cAMP effectors, PKA and Epac can differentially reg-
ulate a range of distinct intracellular processes [1,5–7]. The differential
activation of such effectors is achieved through gradients of cAMP
formed by spatially distinct sub-populations of both adenylyl cyclase
and cAMP degrading phosphodiesterases [1,8]. 9 different PDE sub-
families are capable of degrading cAMP and, in addition to exhibiting
cell-type speciﬁc patterns of expression, they are differentially located
in cells, conferring distinct roles upon enzymes from this super-familyy).[2,3,9–13]. Differences in intracellular targeting, coupled with regulated
changes in both their activity and targeting elicited by post-translational
modiﬁcation, place PDEs ﬁrmly as critical enzymes regulating cellular
function [1]. Indeed, the ability to generate inhibitors selective for
each PDE sub-family has been judiciously exploited in order to both
generate therapeutic agents and garner understanding of the functional
signiﬁcance of these enzymes [3,9,14].
Members of the PDE4 enzyme family play a pivotal role in cell func-
tioning. These enzymes are encoded by four genes (PDE4A, PDE4B,
PDE4C, PDE4D), which generate over 20 distinct isoforms through alter-
nate mRNA splicing and the use of distinct promoters [1,2,9,10,15–18].
PDE4 isoforms critically deﬁne the compartmentalization of cAMP
signalling through their ability to be recruited to speciﬁc signalling
complexes, where they shape cAMP gradients in a temporal and spatial
manner [1]. As such, individual isoforms have speciﬁc, non-redundant
roles acting in deﬁned intracellular compartments; as elucidated
Fig. 1. PDE4 dimerizes in living cells. Yeast 2-hybrid experiments using PDE4D5 as both
‘bait’ and ‘prey’. PDE4D5 was expressed unmutated (“wild-type”) or with the indicated
point mutations. PDE4D5 was expressed unmutated (“wild-type”) or with the indicated
deletion or point mutations. All patches in each columnuse identical ‘prey’ and all patches
in each rowuse identical ‘bait’, as described inMaterials andmethods. Controls are vectors
alone and standards are RasV12–Raf, as done before by us [57]. Positive interactions,
assessed with a ﬁlter β-galactosidase assay, produce blue patches, while negative interac-
tions produce pink patches. (a) Full-length PDE4D5 (amino acids 1 to 749; “long”), or
PDE4D5 lacking its uniqueN-terminal domain andUCR1, but containingUCR2 and the cat-
alytic region (amino acids 206 to 747 of PDE4D5; “short”), was expressed as either a fusion
to LexA (rows) or to GAL4 (columns) and the various mutants tested for interaction.
(b) The EELD:AALA mutant reﬂects that ablating the UCR1:UCR2 interaction [49] while
the VFLL:AAAA mutation reﬂects that used to ablate PDE4D3 dimerization [42]. This
shows data typical of experiments performed at least 3 times.
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displacement approaches [19–22]. Their functioning in these distinct
locales is dynamically regulated through phosphorylation by kinases
such as PKA [23–26], Erk [27–29], MK2 [30,31] and AMPK [30] as well
as modiﬁcation by ubiquitination [32] and sumoylation [33].
Many proteins can undergo dimerization, which can lead to func-
tional differences [34]. In this regard, enzymes from the various PDE
families have a highly conserved catalytic unit and many sub-families
are also characterized by distinct, paired domains located N-terminal
to this. These include the Ca2+/calmodulin binding domains of PDE1,
the Gaf domains of PDE2, PDE5, PDE6, PDE10, PDE11 and the UCR1/2
domains of PDE4 [2,9,15,17]. Such domains have been implicated in
dimer formation [35–46].
Alternative mRNA splicing of all four PDE4 genes yields a plethora of
isoforms. These can be sub-categorised as ‘long’ forms that possess both
UCR1 and UCR2 regulatory domains, ‘short’ forms that lack UCR1 and
‘super-short’ forms that lack UCR1 and have a truncated UCR2 [1,3,9,
10,14–16,18,47]. Also identiﬁed are ‘dead-short’ forms that lack both
UCR1 and UCR2 and have a truncated catalytic unit, making them
catalytically inactive [48].
There is now good evidence that PDE4 isoforms can form dimers
[41–43]. These elegant studies have shown that dimerization in cells is
restricted to the long, but not the short, isoforms as UCR1 is fundamen-
tal to this process. Consistent with this, 2-hybrid studies using isolated
domains have demonstrated that UCR1 can interact with UCR2 and
this might, through trans interaction, facilitate assembly of a long
isoform dimer [49]. Notwithstanding the apparent requirement for
UCR1, X-ray crystallographic analyses of active, but highly truncated
PDE4 core catalytic units, reveal that the isolated catalytic domain can
dimerize, at least under crystallisation conditions, despite the absence
of UCR1 and UCR2 [50]. The dimerization interface within the catalytic
unit comprises a focal contact surface at a C2 symmetry axis that is
bounded at each end by an Asp/Lys charge pairing that is conserved in
all four PDE4 sub-families [50].
Here we use two novel approaches to gain further insight into the
nature of PDE4 dimers formed in living cells, focusing on the widely
expressed PDE4D5 long isoform as an exemplar [51]. Amongst other
things, this isoform has particular functional importance in regulating
the β2-adrenoceptor through its ability to bind to the β-arrestin signal-
ling scaffold [52–56], and also in the migration and polarity of cells
through its ability to bind to the RACK1 signalling scaffold [21,32,53,
56,57]. In one approach, which we describe here, we employed a yeast
2-hybrid methodology to evaluate dimerization in living cells and, in a
second approachwe used scanning peptide array analyses to determine
the details of the PDE4 dimerization site located in the long form-
speciﬁc UCR1 domain. These studies have allowed us to engineer a cat-
alytically active mutant form of PDE4D5 that, unlike the native dimeric
enzyme, exists as a monomer in living cells.
2. Materials and methods
2.1. Materials
Primary antibodies used are rabbit-polyclonal anti-VSV (Abcam Ltd.,
Cambridge, CB4 0FL, UK), mouse polyclonal anti-HA (Covance, Alnwick,
NE66 2JH, UK), mouse anti-FLAG-horseradish peroxidase conjugate and
VSV (vesicular stomatitis virus)-afﬁnity agarose beads were from
Sigma (Gillingham, Dorset, SP8 4XT, UK). Anti-GST antibody (Santa
Cruz/Insight Biotechnology Ltd, Wembley, Middlesex HA9 7YN, UK).
Secondary antibodies used are anti-mouse horseradish peroxidase
linked Ig (GE Healthcare, Amersham Place, Little Chalfont Bucks, HP7
9NA, UK) and anti-rabbit horseradish peroxidase linked Ig (Sigma,
Gillingham, Dorset, SP8 4XT, UK). Stock solutions of rolipram were
prepared in DMSO. Bradford reagent was from Bio-Rad (Hemel
Hempstead, Herts, HP2 4PD, UK). Polyfect transfection reagent was
from Qiagen (Lloyd Street North, Manchester M15 6SH). Proteaseinhibitor tablets were from Roche. Plasmid DNA was prepared using
the QIAprep® Spin Miniprep kit from Qiagen (Lloyd Street North,
ManchesterM15 6SH). [8-3H[cAMPwas fromGEHealthcare (Amersham
Place, Little Chalfont Bucks, HP7 9NA, UK) and unlabelled cAMP together
with all other biochemicals were from Sigma (Gillingham, Dorset, SP8
4XT, UK). NuPAGE was from Invitrogen (Paisley PA4 9RF, UK). ECL
reagents were from Pierce/ThermoFisher (Northumberland, NE23
1WA, UK).
2.2. Yeast 2-hybrid analyses
Yeast 2-hybrid techniques are identical to those used previously
by us to identify and analyse protein–protein interactions [57,58]. In
all experiments, one of the two interacting proteins was expressed
as “bait”, as a LexA DNA-binding domain fusion. The second protein
was expressed as “prey”, as a GAL4 activation-domain protein. In
some experiments, a third protein (i.e., either RACK1 or β-arrestin2)
was also expressed, but as a native species and not as a fusion pro-
tein. All bait were expressed either in pLEXAN or in pBridge as LexA
DNA-binding domain fusions. All prey were expressed in pGADN as
GAL4 activation-domain fusions. All non-fusion co-expressed proteins
were expressed in pBridge (i.e., pBridge expresses two proteins, one
as a LexA DNA-binding domain fusion and the other with only a nu-
clear localization signal). All proteins were targeted to the nucleus.
Fig. 2. Delineation of PDE4D5 dimerization sites by peptide array. An immobilized library of 25-mer peptides sequentially shifted by 5 amino acids along the entire sequence of PDE4D5
was probed with either puriﬁed PDE4D5-GST or GST alone. Dark spots represent areas of interaction between PDE4D5-GST and the PDE4D5 peptide array. Areas of interaction are iden-
tiﬁed by a colour codewhere red represents UCR1, blue represents UCR2 and green represents sequenceswithin the catalytic unit. No interactionwas detected betweenGST alone and the
PDE4D5 peptide array (data not shown).
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ﬁgures, standards were added (the oncoproteins RAS and RAF1). All
interactions were evaluated in the Saccharomyces cerevisiae strain,
L40 with our standard ﬁlter β-galactosidase assay. Except where indi-
cated otherwise, all experiments shown here have been repeated at
least twice, with identical results. In the experiments in Fig. 6e, a
quantitative β-galactosidase assay was used, as we have described
previously [49].
All mutations in PDE4D5 were generated by the circular mutagene-
sis method, using Pfu polymerase (Agilent Technologies) and were
veriﬁed by sequencing prior to use.2.3. SPOT synthesis of peptides and peptide array probing
Peptide libraries were generated by automatic SPOT synthesis on
Whatman 50 cellulose membranes using Fmoc (9-ﬂuorenylmethyloxycarbonyl) chemistry with the Autospot-Robot ASS 222 (Intavis
Bioanalytical Instruments, 50933 Koeln, Germany). The interaction of
peptide spots with GST and GST-fused puriﬁed proteins by overlaying
the cellulose membranes with 10 μg/ml of recombinant protein was
determined as described previously by us in some detail [32,52,53,
59–62]. Bound recombinant proteins were detected with speciﬁc
primary antisera and complementary HRP-coupled secondary antibody
as for immunoblotting.2.4. Cell culture and transfection
HEK (human embryonic kidney)-293 cellsweremaintained inDMEM
(Dulbecco's modiﬁed Eagle's medium) supplemented with 2 mM gluta-
mine, 10% (v/v) foetal bovine serum (Sigma), 1% penicillin/streptomycin
(100 units/ml) in an atmosphere of 5% CO2 and 37 °C. All cells were
transiently transfected with PolyFect.
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Cells were transiently transfected with wild-type PDE4D5-VSV,
PDE4D5-FLAG, PDE4D5-HA and the indicated mutant forms. At
48 h post-transfection, cells were lysed using a 3T3 lysis buffer
containing 20 mM HEPES (pH 7.4), 50 mM NaF, 10% (v/v) glycerol,
1% (w/v) Triton X-100, 10 mM EGTA, 30 mM sodium pyrophosphate
and protease inhibitor cocktail. Cell lysates were pre-cleared with
Protein G beads and then used for immunoprecipitation of VSV-
tagged proteins. Cell lysates were incubated with VSV-afﬁnity
agarose beads for 2 h at 4 °C. After centrifugation at 18,000 g for
3 min, beads were washed three times with lysis buffer. Laemmli
[63] sample buffer was used to elute the immunoprecipitated VSV-
fusion proteins and the resulting material was resolved by NuPAGE.
Proteins were transferred on to nitrocellulose membranes and
subjected to Western blotting with detection by enhanced
chemiluminescence (ECL).2.6. PDE activity assay
PDE activity was measured using radioactive cAMP hydrolysis assay
that has been described previously in detail [64,65].Fig. 3. Alanine scanning pinpoints amino acids that are important for PDE4D5 dimerization. Al
aspartate if residue is an alanine) was undertaken on three PDE4D5 self-association domains
represent areas of interaction between PDE4D5-GST and the PDE4D5 peptide array. Cont = c
to the native sequence. Data represents the mean plus S.E. from three independent experimen
not shown).3. Results
3.1. PDE4D5 forms a dimer in living cells
Using both immunoprecipitation and gel ﬁltration approaches with
PDE4D2 (short) and PDE4D3 (long) as exemplars, it has been proposed
that long, but not short, PDE4 isoforms adopt a dimeric state when
isolated from cell extracts [41–43]. Consistent with such a notion, when
we expressed the long PDE4D5 isoform in yeast, as both bait and prey
in a 2-hybrid assay, it is clearly evident that PDE4D5 monomers interact
to form dimers in living cells, yielding blue, β-galactosidase positive,
patches (Fig. 1a, b).
It has been shown that the UCR1 domain, which is lacking in short
forms, is critical to the formation of dimers [41–43]. While we show
here that the ‘long’ PDE4D5 isoform can interact strongly with itself in
living cells to form dimers, as exempliﬁed here using yeast two-hybrid
assays (i.e., can dimerize; Fig. 1a), in agreement with previous studies
of others [41–43], a construct that we engineered for this study to
approximate a short form, critically by the removal of the UCR1 of
PDE4D5, exhibited a profoundly attenuated ability to dimerize in two-
hybrid assays (Fig. 1a). Thus, as previously stated by others [41–43],
the dimerization of PDE4 long forms requires UCR1 while PDE4 short
forms, which lack UCR1, fail to dimerize signiﬁcantly.anine scanning analysis (where each of the indicated residues is replaced with alanine or
highlighted in Fig. 2. Arrays were overlayed with PDE4D5-GST or GST alone. Dark spots
ontrol spot chosen from data depicted in Fig. 2 and where all 25 amino acids correspond
ts. No interaction was detected between GST alone and the PDE4D5 peptide array (data
Fig. 3 (continued).
760 G.B. Bolger et al. / Cellular Signalling 27 (2015) 756–769We have previously demonstrated that UCR1 and UCR2 interact to
form a functional module [49]. Critical to this are 3 negatively charged
residues in UCR2 that are located within a contiguous cluster (218-
EELD-221; PDE4D5 numbering), which bind to a positive patch within
the largely hydrophobic UCR1 and whose mutation, to alanine, ablates
UCR1:UCR2 interaction [49]. Mutating these residues, all to alanine, in
PDE4D5 (EELD:AALA), however, failed to ablate PDE4D5 dimerization,
as assessed in 2-hybrid assays in the present studies (Fig. 1b).
Richter and Conti [42] employed a helical wheel analysis in order to
direct amutagenesis approach to gain insight into residues important in
determining UCR1:UCR2-based long form dimerization. Their M2
mutation, made in PDE4D3, targeted the conversion of a VFLL set of
non-contiguous residues (PDE4D3 numbering is V100, F104, L152,
L155; PDE4D5 numbering is V172, F176, L224, L227) to alanine, which
ablated dimer formation in their hands [42]. Here we investigated the
cognate mutant in PDE4D5 and, consistent with their discovery, we
showed that it did indeed compromise dimerization of this long form
in a living cell assay (Fig. 1b).
Wehave found that inmost if not all instanceswhere PDE4 is involved
in binding to a partner protein then more than one binding surface is in-
variably involved, which contributes to binding ﬁdelity [53,54,59–61].
Thus, as PDE4D5 dimerizationwas not fully ablated bymutation of either
of the contiguous EELD or non-contiguous VFLL clusters (Fig. 1b), wedecided to investigate, using peptide array technology, whether other
regions of PDE4D5 were involved in stabilising its dimeric state.
3.2. Probing PDE4 long form interaction interfaces using scanning peptide
arrays
In order to uncover further interactions required for oligomeric self-
association of PDE4D5we used peptide array analysis, which provides a
novel and powerful technology for gaining insight into the basis of
speciﬁc protein–protein interactions [32,52,53,59–62]. In order to do
this a library of overlapping peptides (25-mers), each shifted by 5
amino acids across the entire 745 amino acid sequence of PDE4D5
was spot-synthesised on cellulose membranes. This immobilized
peptide library was subsequently probed with a puriﬁed, recombinant
GST-PDE4D5 fusion protein whose binding to protein spots was
assessed, immunologically, with positive interactions identiﬁed as
dark spots. Undertaking such an analysis we identiﬁed positive interac-
tions within not only UCR1 but also the UCR2 and catalytic regions
(Fig. 2).
To deﬁne further the speciﬁc amino acids involved in PDE4D5
binding to this peptide array, we screened a family of peptides derived
from distinct 25-mer parent peptides that positively interacted with
PDE4D5. The peptide progeny from speciﬁc 25-mer parents were
Fig. 4. Characterization of ‘Dimerization Domain’ (DD) mutants. (a) Amino acid co-ordi-
nates for the 4 DD regions on the PDE4D5 protein used throughout this study.
(b) Mutations in individual DD domains do not ablate the interaction. The amino acids
in each individual DD domain were mutated to alanine and tested for their effect on
PDE4D5 dimerization in 2-hybrid assays, as in Fig. 1. (c) Mutations in combinations of
DDdomains do not ablate the interaction. Combinations of DDdomainmutantswere test-
ed for their effect on PDE4D5 dimerization. This shows data typical of experiments per-
formed at least 3 times.
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sive amino acids in the sequence to form a scanning peptide array that
was probed with recombinant GST-PDE4D5 fusion protein. Sections of
these arrays are shown here to demonstrate those amino acids whose
substitution to alanine engendered a signiﬁcant and reproducible
compromised interaction with GST-PDE4D5 (Fig. 3; highlighted by a
red asterisk). This identiﬁed R173 and N175 within UCR1; E228, T229
and L230 in UCR2 and L306, M307, H308 and K323, T324, E325 within
the catalytic unit (Fig. 3).
We then set out to determine whether these were involved in
PDE4D5 homodimerization, evaluating four regions that we termed
DD1 (R173, N174 and N175), DD2 (E228, T229 and L230), DD3 (L306,
M307, H308) and DD4 (E228, T229 and L230) (Fig. 4a). Firstly we
mutated, to alanine, each set of residues within these clusters and
assessed the regions individually as to whether they compromised
dimerization,which they appeared not to do (Fig. 4b). Thenwe assessed
combinations of 3 of these clusters and, ﬁnally, all four DD clusters (in
the quad-PDE4D5 construct), when mutated to alanine in order to
determine whether they compromised dimerization, which they
appeared not to do (Fig. 4c).3.3. Demonstrating that the ion pair stabilising the dimeric surface evident
in crystallographic studies of the core PDE4D catalytic unit is required for
PDE4D5 dimerization in living cells
While aggregation of full length PDE4 isoforms hasmilitated against
structural studies of such physiologically relevant species, there is a
wealth of 3-D structural data on truncated species that represents the
highly conserved core catalytic unit found in each of the four PDE4
sub-families (see e.g. [66]). Interestingly, these studies reveal that the
‘naked’ PDE4 catalytic units crystallise from solution as homo-dimers.
Detailed examination of the dimerization interface showed that it
comprises a highly organised focal network of hydrogen bonded inter-
actions and hydrophobic contacts augmented by a critical Asp–Arg ion
pairing [50], which in PDE4D5 involves Asp463 and Arg499 (Fig. 5a).
While these two charged residues appear to play no role in maintaining
the structural integrity of an individual catalytic unit, mutation of either
Asp:Arg or Arg:Asp ablated the ability of a PDE4D core catalytic
construct to dimerize [50]. Interestingly, this site was not discovered
in our peptide array analyses, which at least in part likely arises from a
failure of short 25-mer peptides to conserve the very precise 3-D confor-
mation of the PDE4 catalytic subunit in this tightly folded region.
We thus set out to investigate any potential role of this ion pair in
the dimerization of full-length PDE4D5 (Fig. 5b). The R449D mutation
failed to ablate dimerization when this mutant was expressed either
alone or with native PDE4D5 or quad-PDE4D5 (where all four DD
sites identiﬁed by peptide array analyses were mutated to alanine; see
Fig. 4a for details) and, ﬁnally, a R499D-quad-PDE4D5 construct
(Fig. 5b). However, in marked contrast to either the R499D-PDE4D5
or quad-PDE4D5 construct, which underwent homo-dimerization, we
discovered that incorporating both sets of disruptions in the R499D-
quad-PDE4D5 construct then it singularly failed to undergo dimeriza-
tion (Fig. 5b). Furthermore, the R499D-quad-PDE4D5 mutant failed to
interact with the quad-PDE4D5 mutant, although it did interact with
the R499D-PDE4D5mutant (Fig. 5b). Itwould thus appear that to ablate
dimerization of PDE4D5 effectively in living cells then disruption of the
ion pair stabilised catalytic unit dimerization interface uncovered in
crystallography studies is needed together with disruption of key re-
gions located N-terminal to the catalytic unit.
It could be argued that disruption of the ion pair formed by Asp463
and Arg499 in the PDE4D5 catalytic unit might indirectly compromise
dimerization by undermining the overall structural integrity of the
domain. Against such a contention, crystallography studies show that
these residues do not maintain the tertiary structure of the catalytic unit
[50]. Nevertheless we set out to address this question directly through
charge reversal rescue experiments. If indeedmaintenance of the catalytic
domain tertiary structure is independent of the residue identity at posi-
tions 463 and 499, then it should be possible to establish a reversed
D499-R463 salt bridge to reinstate dimerization with the R499D-quad-
PDE4D5 mutant. Pleasingly our experiments conﬁrmed this (Fig. 5c).
Thus, whereas the D463R-quad-PDE4D5 and R499D-quad-PDE4D5 mu-
tants failed to homodimerize when individually expressed, dimerization
capacity was indeed rescued when the two constructs were jointly
expressed, through establishment of a complementary heterodimeric
D463-D499:R463-R499 pairing at the catalytic domain interface.
We also noted that neither the R499D-quad-PDE4D5 nor the D463R-
quad-PDE4D5mutants interactedwith the DD-quad-PDE4D5mutant but
both were capable of interacting with wild-type PDE4D5 (Fig. 5c). An
interesting difference however, was that while R499D-quad-PDE4D5
interacted equally as well with wild-type-PDE4D5 and the single R499D
mutant (Fig. 5b), D463R-quad-PDE4D5 showed compromised binding
to the single D463R-PDE4D5 mutant compared to wild-type-PDE4D5
(Fig. 5c). Interestingly, the single mutations of each of these residues
forming the catalytic dimer-stabilising ion pair behaved similarly in that
each single mutant showed, compared to wt-PDE4D5, reduced binding
when expressed individually or paired with quad-PDE4D5 (Fig. 5b, c).
These studies show that single mutations in this ion pair have dramatic
762 G.B. Bolger et al. / Cellular Signalling 27 (2015) 756–769and speciﬁc consequences for the PDE4D5 dimerization process, which
clearly requires an additional site located N-terminal to the catalytic unit.
3.4. The DD1 motif in UCR1 is critical for PDE4D5 dimerization
We next set out to determine whether all of the DD regions
identiﬁed in our peptide array analyses are critical for PDE4D5 homo-Fig. 5. Structure of dimeric PDE4 core catalytic domain assembly and the effect of the R449D
cilomilast inhibitor (blue surface) is shown (PDB: 1XOM; [73]). Assembly is centred on a C2 s
focal interaction are highly organised through a network of hydrogen bonds. Helix-11 make
D463. Key residues contributing to the dimerization interface are only partially conserved in o
sponding region (dotted circle) in PDE2 and PDE5 is conformationally mobile and dynamically
(ii) Surface rendition derived from (i) highlighting the core catalytic domain dimerization inte
(b)Mutations in PDE4D5were tested for their ability to ablate dimerization: The ‘DD-quad’mut
in Fig. 4a. The R449D-PDE4D5mutant and the combined R499D+DD-quad-PDE4D5mutant w
R499D-PDE4D5mutant nor the DD-quad-PDE4D5mutant ablated the interaction, but that the c
of the charge effect of the R499D-PDE4D5 mutant by the D463R-PDE4D5 mutant. The D463R-P
The data show that the D463R-PDE4D5mutant effectively rescued the ablation of the interactio
experiments performed at least 3 times.dimerization using constructs where the indicated combinations of
DD1-4 amino acids were mutated to alanine (see details of residues in
Fig. 4a). Probing with the R499D-quad-PDE4D5 construct we showed
that while it failed to interact with itself (R499D-quad-PDE4D5) and
also failed to interact with DD-quad-PDE4D5 and DD1:DD2:DD3-
PDE4D5, it was able to interact with DD2:DD3:DD4-PDE4D5 (Fig. 6a),
suggesting that of these regions identiﬁed by peptide array then themutation on dimerization. (a) (i) The dimeric PDE4D core catalytic domain with bound
ymmetry axis (asterisk) at the junction of helices-9 and -10; residues contributing to the
s a single point of contact in the dimer through R499 in a salt bridge to H-loop residue,
ther PDE families. In contrast to the highly organised H-loop structure in PDE4, the corre-
folds into the catalytic pocket (blue arrow) to regulate catalytic activity (see Discussion).
rface on one subunit (orange) and contact residues from the second subunit (green stick).
ant is a combination of all four DDdomainmutationswhere each are described individually
ere also studied. Two-hybrid assays were used as in Fig. 1. The data show that neither the
ombined R499D+DD-quad-PDE4D5mutantmarkedly ablated the interaction. (c) Rescue
DE4D5 mutant was tested singly and in combination with the DD-quad-PDE4D5 mutant.
n seen with the combined R499D+DD-quad-PDE4D5mutant. This shows data typical of
Fig. 5 (continued).
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region. Consistent with the importance of DD1, we showed that while
R499D-quad-PDE4D5 failed to interact with either DD1:DD3:DD4-
PDE4D5, DD1:DD2-PDE4D5 or DD1:DD3-PDE4D5, it did interact with
DD2:DD3-PDE4D5, DD2:DD4-PDE4D5 and DD3:DD4-PDE4D5 (Fig. 6b,
c). Finally, R499D-quad-PDE4D5 failed to interact with the single DD1
cluster mutation of DD1-PDE4D5, while it interacted with all of the
single DD2-PDE4D5, DD3-PDE4D5 and DD4-PDE4D5 cluster alanine
mutations (Fig. 6c).
On this basis we probed the DD1-PDE4D5 mutation further with
other mutant PDE4D5 species. These showed (Fig. 6d) that while DD1-
PDE4D5 interacted with wild-type-PDE4D5 it not only failed to interact
with R499D-quad-PDE4D5 but also failed to interact with R499D-DD1-
PDE4D5, showing that the minimal mutation of R499D and DD1 is all
that is required to ablate PDE4D5 dimerization in living cells.
To gain further insight into the importance of the three amino acid
residues mutated in DD1 (Fig. 4a) we assessed them through either
individual or paired alanine mutations in 2-hybrid experiments involv-
ing paired R499D-X-PDE4D5 constructs, where ‘X’ was either R173A or
N174A or N175A (Fig. 6e). This clearly showed that alanine mutation
of any of these three residues severely compromised PDE4D5 dimeriza-
tion, with the effects of R173A and N174A being most profound (Fig. 6e).
3.5. PDE4D5 dimerization and its disruption in mammalian cells
Having demonstrated PDE4D5 dimerization for the ﬁrst time in
living cells, we set out to determine whether the R499D-quad-PDE4D5 and R499D-DD1-PDE4D5 species were monomeric when
expressed in mammalian cells (Fig. 7). Richter and Conti have previ-
ously determined [41,42] that when the PDE4D3 long isoform is
transiently expressed in mammalian cells, as two differently tagged
species, then immunoprecipitation using antibodies to one tag co-
immunoprecipitated both tagged forms of PDE4D3, consistent with
its dimerization. We show here that in HEK293 cells transiently
expressing both ﬂag- and vsv-tagged PDE4D5 long isoform constructs,
then immunoprecipitation with one antisera co-immunoprecipitates
both tagged forms of PDE4D5 (Fig. 7a). Such studies demonstrate
the dimerization of PDE4D5, which is consistent with the studies
and conclusions of Richter and Conti [41,42] using the PDE4D3 long
isoform.
Such co-immunoprecipitation is ablated when the ﬂag-Quad-
R499D-PDE4D5 construct is paired with vsv-Quad-PDE4D5 and severe-
ly compromisedwhen either theﬂag-Quad-R499D-PDE4D5 construct is
paired with vsv-WT-PDE4D5 (Fig. 7b) or ﬂag-DD1-R499D-PDE4D5
construct is paired with vsv-DD1-R499D-PDE4D5 (Fig. 7c). Such data
are consistent with the 2-hybrid studies showing that dimeric PDE4D5
can be forced into a monomeric state by DD1 and R499D mutation.
The conversion of PDE4D5 into amonomeric species by these discrete
mutations has little effect on the efﬁcacy of the pan-PDE4 inhibitor [14],
rolipram to inhibit this isoform (Fig. 8). Expressed transiently in HEK
293 cells, dimeric wild-type PDE4D5 exhibited an IC50 value of 1.4 ±
0.2× 10−7 M while monomeric DD1-R499D-PDE4D5, with only four
amino acids mutated, exhibited an IC50 value of 2.3 ± 0.3 × 10−7 M
(SD, n = 3 separate determinations).
Fig. 6.Key effects of DD1 regionmutants on dimerization. (a,b,c) The effects of various combinations of DD domainmutants were studied in ﬁlterβ-galactosidase assays for their effect on
their interactionwith R499D+DD-quad-PDE4D5mutant. Two-hybrid assayswere used as in Fig. 1. The data show that combinations containingmutations inDD1 ablated the interaction,
whilemutations in other combinations of DD domains hadminimal effect. (d) Comparison of the DD1-PDE4D5mutants in cis and transwith the R499D-PDE4D5mutant. The R499D, DD-
quad, andDD1 PDE4D5mutantswhen singly and in combination,were tested against the same array ofmutants. The data show that the DD1-PDE4D5mutant blocks the interactionwhen
present in either half of the dimer (i.e., regardless ofwhether it is present in the ‘prey’ or ‘bait’ construct.) (e) Quantitative analysis of DD1 region individual amino acidmutants: Individual
amino acids in PDE4D5-DD1 (sequence RNN, Fig. 4a) were mutated to alanine and tested in a quantitative β-galactosidase assay for their effect on their interaction with R499D + DD-
quad-PDE4D5. The data show that restoration of one or two amino acids to wild-type increases the interaction, at least in some cases, but never back to wild-type. This suggests either
that (1) All three amino acids in the RNN motif contribute directly to the interaction; or that (2) Even single amino acid mutations in this area cause sufﬁcient localized distortion of
the PDE4D5 structure that they attenuate the interaction. This shows data typical of experiments performed at least 3 times.
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Many proteins undergo dimerization and some even undergo
oligomerization that can lead to tertiary changes in structure, which
may then elicit functionally important alterations in their activity and
distribution [34]. Such changes can have either physiological or patho-
physiological consequences.Cyclic AMP phosphodiesterases provide the sole route for degrading
the ubiquitous second messenger, cAMP in cells [1–3,9]. As such they
are poised to play critical regulatory roles. Members of the ubiquitously
expressed cAMP-speciﬁc PDE4 family are of particular importance,
inﬂuencingmajor processes such as inﬂammation, learning andmemory,
cell cycle and the cardiovascular system [14,16,18,67]. Critical to this is the
ability of speciﬁc isoforms to act as nodes that respond to inputs from
Fig. 7. PDE4D5 dimerization in mammalian cells. The indicated Flag and vsv-tagged PDE4D5 wild-type and mutant constructs were co-expressed in HEK293 cells. Cells were then
disrupted and lysates taken for either immunoblotting with both anti-Flag and anti-vsv antisera or immunoprecipitated with anti-vsv antisera prior to immunoblotting with both anti-
Flag and anti-vsv antisera. The data shown are representative of experiments performed at least three times using different transfected cell preparations.
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phosphorylation [10,18,30,31]. They also perform a pivotal role in
underpinning compartmentalised cAMP signalling by determining
targeted cAMP degradation [1,12]. This occurs as a consequence of their
ability to be sequestered at speciﬁc intracellular sites/‘signalosomes’ in
an isoform-speciﬁc fashion through protein–protein interactions with
distinct anchoring proteins.
The four-gene PDE4 family encodes over 20 different isoforms that
are deﬁned by their unique N-terminal regions together with sub-
family speciﬁc variations in sequence of the catalytic unit, C-terminal
and linker regions [17]. Catalytically active species can then be
categorised into either long forms, which possess the regulatory UCR1
and UCR2 regions and short forms that lack UCR1. The UCR1/UCR2
module plays a pivotal role in regulating PDE4 catalytic activity, where
the UCR2 region has an auto-inhibitory role [9,16,17,47]. Regulation is
mediated through multi-site phosphorylation of UCR1, where
phosphorylation by PKA elicits both activation [23–26] and an ability
to ablate inhibitory phosphorylation of the PDE4 catalytic unit by Erk
[27,29]. UCR1 also provides the site for phosphorylation by MK2 [31],which serves to attenuate the degree of activation conferred by PKA
phosphorylation and, in the case of PDE4D5, a site for mono-
ubiquitination by the β-arrestin-sequestered E3 ligase, Mdm3, which
gates poly-ubiquitination of the PDE4D5 isoform-speciﬁc N-terminal
region [32].
A growing body of evidence, garnered from biochemical studies,
indicates that PDE4 long isoforms adopt a dimeric quaternary structure
and that UCR1 performs a pivotal role in underpinning this [41–43]. In
contrast, PDE4 short forms appear to be exclusively monomeric. 2-
hybrid and biochemical approaches akin to those described in this
study have shown that UCR1 and UCR2 interact with each other [49]
and, as such, this interaction has the potential to contribute to either
dimer formation when binding in a trans conﬁguration or to stabilise a
monomer when binding in a cis conﬁguration. Indeed, the charged
residues suggested to stabilise UCR1:UCR2 interaction may reﬂect
those important for stabilising a monomeric conﬁguration where
UCR1 interacts internally with UCR2 in a cis-conﬁguration, as their
mutation in the PDE4D3 long form failed to ablate its ability to dimerize
[41] and, similarly, we conﬁrm this herewith PDE4D5 (Fig. 2). However,
Fig. 8. Dimeric and monomeric PDE4D5 are similarly inhibited by rolipram. Lysates of
HEK293 cells transfected to express either wild-type- (dimeric) or DD1-R499D- (mono-
meric) PDE4D5 were used to assess the ability of increasing concentrations of rolipram
to inhibit their activity using 1 μM cAMP as substrate. Data showsmeans± SD for a single
experiment with triplicate assays. Data from replicates of such experiments was used to
determine IC50 values of 1.4 ± 0.2 × 10−7 M for dimeric wild-type PDE4D5 and 2.3 ±
0.3 × 10−7 M for monomeric DD1-R499D-PDE4D5, with only four amino acids mutated
(SD, n = 3 separate experiments).
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identify a critical Arg173, Asn174 and Asn175 cluster in UCR1
(PDE4D5 numbering) whosemutation, to alanine, ablates dimer forma-
tion as long as the catalytic unit dimerization site is co-disrupted bymu-
tation of one or both of the charged species that stabilise this surface
(Asp463 and Arg499 in PDE4D5). Unfortunately there is no complete
structure of UCR1 andUCR2 thatwould allowus to deﬁne this dimeriza-
tion surface and the residues that these groups might link to. Possibili-
ties include UCR1 interacting with conserved regions on either itself
or UCR2 or the catalytic unit. However, one would presume that the in-
teraction is driven by charge–charge interaction involving Arg173 and
H-bonding involving both Asn174 and Asn175. We believe that the
RNN motif identiﬁed here in peptide array experiments and conﬁrmed
by mutagenesis as important in PDE4 dimerization represents a critical
core unit whose mutation causes minimal overall change in the struc-
tural integrity of the enzyme. This is because RNN:AAAmutation of itself
does not alter the dimerization status of PDE4D5 until it co-presents
with the R:D catalytic dimer site mutation.
The VFLL:AAAA combination mutation identiﬁed previously as
ablating dimerization in PDE4D3 [42], and shown here to seriously
compromise it in PDE4D5 (Fig. 1), may exert its profound effect by
directly destabilising a dimerization interface involving elements from
UCR1 and UCR2. Thus, based on sequence analysis with a helical
wheel model [42], the valine and phenylalanine from this residue set
have been tentatively mapped to a contiguous hydrophobic surface in
a postulated UCR1 C-terminal α-helix [UCR1(C)]; the two leucines
were proposed tomap to a complementary hydrophobic surface in a he-
lically organised N-terminal half to UCR2 [UCR2(N)]. It is therefore
tempting to suggest that theUCR1(C) andUCR2(N) regionsmay assem-
ble as a 4-helix bundle in dimeric PDE4 long forms (vide infra), such that
hydrophobic surfaces running along the proposed helices are a major
contributory feature to a dimerization interface. While the VFLL residue
set may directly contribute to such an interface within a helix bundle,
noneof these residueswere identiﬁed as individually critical for interac-
tion when mutated separately in our alanine scanning peptide array
analysis. At present we cannot deﬁnitively state whether the combined
mutation of these residues compromises dimerization because they
directly contribute to a binding interface or because they indirectly per-
turb adjacent regions that do. In particular the valine and phenylalanine
of the VFLL set immediately ﬂank the DD1 site (172-VRNNF-176) in
UCR1(C), while the two leucines immediately precede the DD2 motif
(224-LDQLETL-230) that we have identiﬁed in UCR2(N).
The RNN UCR1 dimerization motif identiﬁed here in PDE4D long
forms is identical in PDE4B long forms (e.g. Arg165, Asn166 and Asn167
cluster in PDE4B3) and highly conserved in PDE4A (e.g. Arg192, Ser193
and Asn194 cluster in PDE4A4) and PDE4C (e.g. Arg134, Ser135 and
Asn136 cluster in PDE4C3) long forms where the central Asn group is re-
placed by Ser, which is also capable of H-bond formation. Intriguingly, in
these two sub-families then the Ser group can potentially be modiﬁed by
phosphorylation,whichmight provide ameans of dynamically regulating
dimerization in these two PDE4 sub-families.
A fundamental discovery uncovered by our approach is the critical
importance of the catalytic unit dimerization interface, ﬁrst identiﬁed
from crystallographic analyses [50], to the stabilisation of PDE4 long
isoforms dimerization expressed in living cells. This is stabilised by an
ion pair, namely Asp463 and Arg499 in PDE4D5, binding in a trans
conﬁguration [50]. As with the DD1 cluster in UCR1, this ion pair is
conserved in the catalytic units of all four PDE4 sub-families (see e.g.
Asp498 in PDE4A4, Asp456 in PDE4B3; Asp421 in PDE4C3; Arg534 in
PDE4A4, Arg492 in PDE4B3; Arg457 in PDE4C3). The focal point for
the dimerization interface encompassing the ion pair has been deﬁned
in the core catalytic domain crystal structures and lies at the junction
of helices-9 and-10 (Fig. 5a). Signiﬁcantly, the tertiary structure of this
region, with tightly folded short helices and loops, is expected to be
dependent on its context within an intact core catalytic domain. Loss
of the critical fold to this region in the short 25-mer sequences used inour peptide array assays might thus account for their failure to detect
the dimerization surface encompassing Asp463. Arg499 (in contrast to
Asp463) lies on a long helix (helix-11) and, while preservation of the
helical secondary structure for this region might be reasonable in one
or more of the array peptides, the residue is the sole point of dimer
contact on helix-11 and lies 30 residues C-terminal to the focal residue
set for the dimer interface (460-MYNDSSVLEN-469 … R499). Within
the context of our peptide array, therefore, it is not surprising that
peptides encompassing Arg499 as the single point of contact would
fail to bind the PDE4D5 protein probe. Despite this, the Arg499–
Asp463 ion pairing clearly makes an essential contribution to dimeriza-
tion because the single charge reversal mutation of either one of this
pair of amino acids serves to ablate the functional integrity of the cata-
lytic unit dimer surface (Fig. 5c and see [50]). The acute sensitivity of the
interface to the trans interaction of these two charged residues is further
highlighted by the ability of a second and complementary Asp463Arg
charge reversal mutation to rescue the dimerization capacity that is
compromised by Arg499Asp alone (Fig. 5c).
Although PDE4 core catalytic domain constructs that have been
engineered to remove UCR1 and UCR2 can be crystallised in a dimeric
state, such proteins do not exist as dimers in solution. Similarly, physio-
logical PDE4 short forms that lack UCR1 fail to dimerize to a detectable
extent [41–43]. Interestingly, however, evidence of a small dimer
population, involving the PDE4D core catalytic unit was gained using
glutaraldehyde cross-linking [50]. While this supports the existence of a
monomer–dimer equilibrium involving the catalytic unit, even if it is
heavily biased towards the monomer, irreversible glutaraldehyde cross-
linking will inevitably perturb such equilibrium in favour of dimer detec-
tionby creating a pool of trappeddimers that are removed fromequilibra-
tion with the monomer pool. This suggests that the free energy derived
from engagement of the interface on the core catalytic domain is, on its
own, insufﬁcient to drive a monomer–dimer equilibrium in favour of
the dimer; it takes the added presence of the UCR1 module, found only
in PDE4 long forms, to favour dimer assembly through the establishment
of an extra dimerization interface. This twin interface assembly likely
underpins key regulatory aspects of PDE4 long form enzymology that
involve auto-inhibitory capping of the catalytic pocket by a helical motif
within the C-terminal half of UCR2. Thus, Burgin et al. have acquired crys-
tal structures for the PDE4 core catalytic domain linked to a fragment
from UCR2(C) that strongly support the notion that substrate entry to
the catalytic pocket is gated by UCR2 [68]. In the available structures to
Fig. 9.PDE4 long formdimerizationmodel and sequence key. (a) Cross-cappedmodel for PDE4 long formassembly based on the 3G45UCR2-capped core catalytic domain crystal structure
of Burgin et al. [68]. Sequence analysis ﬁtted to a helical wheelmodel suggests that the UCR1(C) and UCR2(N) regions likely adopt helical 2° structure with extensive hydrophobic contact
surfaces suitable for helix bundle assembly [37]. Inter-helix structural transition [e.g.mediated by phosphorylation (PKA site a; [23–26])] is proposed to control stability of theUCR2(N) cap
and thence gate substrate entry to the catalytic pocket (white oval). The stability of the UCR2 cap is also affected by additional phosphorylation (ERK site b; [28,29,70,71]) and competitive
cappingwith a C-terminal regulatory sequence (CR3; [68])may further inﬂuence enzyme activity. The deﬁnition of LR2 (Linker Region 2)was coined [17] as that region of amino acids that
joins UCR2 to the catalytic unit and is unique to each of the four PDE4 sub-families. (b) Structure of the PDE2 dimer (PDB: 3IBJ, [40]; seeDiscussion). (c) PDE4D5 sequence key, highlighting
domain boundaries [15,47] and residues implicated in PDE4 long formdimer assembly. Residuesmarked: and • are proposed to contribute to extended hydrophobic contact surfaces along
helical 2° structure motifs for UCR1(C) and UCR2(N) [42]. Quadruple alanine mutagenesis of the VFLL set (•) reportedly ablates PDE4D3 dimerization [42] and in the present work also
compromises PDE4D5 dimerization. Sequences identiﬁed as possible dimerization domains in the peptide array studies of the present work are identiﬁed (DD1, 173-RNN-175; DD2,
228-ETL-230; DD3, 306-LMH-308; DD4, 323-KTE-325). PKA and ERK phosphorylation sites are marked (a and b respectively). Focal residues contributing to the core catalytic domain
dimerization interface are marked (*, c, d), where c and d are respectively D463 and R499 and form an important ion pairing that underpins the stability of this interface (cf. Fig. 5a).
767G.B. Bolger et al. / Cellular Signalling 27 (2015) 756–769date the LR2 linker region (Linker Region 2; [17]) that connects UCR2 to
the core catalytic domain is disordered; this, combined with engineering
in the linker region needed to acquire suitable crystals, prevented
unambiguous assignment of the UCR2 capping mode to one or other of
the two possibilities, namely intra-molecular versus inter-molecular.
Nevertheless, an inter-molecular interaction, which would reﬂect cross-
capping within a dimeric assembly, has been proposed as an attractivepossibility [69]. Part of the rationale for that suggestion was the observa-
tion that the two connection sites for themissingN-terminal sequences in
the Burgin structures are perfectly poised for a dimeric assembly of the
UCR2(N) and UCR1(C) helices inferred from the work of Richter and
Conti [42]. Themodel thus implicated for PDE4 long formdimer assembly
is illustrated in Fig. 9a and invokes a 4-helix bundle organisation to the
UCR1(C)/UCR2(N).
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key differences with the established dimer structure for PDE2
(Fig. 9b). PDE2 shares a similar core catalytic domain fold to PDE4, but
the UCR regulatory modules are replaced by tandem GAF domains.
Pandit and co-workers have shown that PDE2 assembles as a dimer
through pairing of the GAF domains so that regulatory cGMP binding
to these units drives structural transition into the core catalytic domain
through a coiled-coil assembly [40]. In particular, the PDE2 catalytic
activity is controlled by regulatory deformation of the H-loop into the
catalytic pocket (Fig. 5a, blue arrows) driven by motion in the coiled-
coil assembly (Fig. 9b). In contrast to PDE2, the regulatory H-loop region
is adapted as a core catalytic domain dimerization interface in PDE4.
Moreover, the helices connecting the PDE2 GAF units to the catalytic
domain are replaced in PDE4 by the UCR2(C) helices and a ﬂexible
linker (LR2; [17]), so that substrate access is controlled byUCR2 capping
rather than by H-loop deformation. Such an assembly would then
provide ameans of controlling PDE4 long form catalytic activity through
PKA phosphorylation-dependent induction of inter-helix structural
transition in the UCR1(C)/UCR2(N) helix bundle to alter the stability
of the UCR2(C) cap on the catalytic pocket.
Absolute conﬁrmation of the cross-capping interaction and elucida-
tion of the structural detail for the proposed UCR1(C)/UCR2(N) helix
bundle assemblywill requiremore advanced structural studies. Howev-
er, our results here combinedwith those of Richter and Conti [42] ﬁrmly
implicate the 172-VRNNF-176 sequence within UCR1(C) and the 224-
LDQLETL-230 sequence within UCR2 as focal contributory elements. A
more extended set of hydrophobic residues proximal to these
sequences has also been implicated by Richter and Conti [42], as
summarised in Fig. 9c, and thus our DD1 triple-alanine mutation of
173-RNN-175 in UCR1 may weaken but not necessarily fully disengage
the UCR interface under circumstances where the core catalytic domain
surface is still fully competent. At present there is no direct evidence to
support H-loop deformatory transitions at the core catalytic domain
dimerization interface, but structural studies of long and short isoforms,
rather than just catalytic units, will be needed in order to fully compre-
hend differences consequent on monomer–dimer inter-conversion.
This will be challenging, given the already demonstrated requirement
for considerable mutagenesis to stabilise the construct in the currently
available UCR2-capped structures [68].
Our peptide array studies also identiﬁed a potential interaction
surface within the PDE4D catalytic unit that we have called DD4
(Figs. 3c, 4a). While mutation studies showed that DD4 did not play a
critical role in stabilising PDE4D5 dimer it is interesting that K323,
which forms part of DD4, provides the site of modiﬁcation by
sumoylation in PDE4D5 [33]. It may be that such a modiﬁcation could
affect this interface in such a way as to have functional consequences
relating to alterations in the dimerization state/structure of PDE4D5.
We show here using PDE4D5 as an exemplar that PDE4 long
isoforms adopt a dimeric state in living cells. This modality is exclusive
to long isoforms as it critically depends upon not only an interaction
involving a site within the conserved PDE4 catalytic unit but also one
within the UCR1 regulatory region unique to PDE4 long isoforms. In
other words, both sites in long forms can each separately stabilise the
dimeric conﬁguration. As such this may provide a fail-safe system for
stabilising the dimeric state in PDE4 long forms. However, they also
offer opportunities for speciﬁc informational inputs to destabilise the
dimeric status, but only if destabilising actions are directed at both of
these sites, which would then lead to the generation of a structurally
and functionally distinct monomeric species. Thus it remains to be dis-
coveredwhether long formmonomer–dimer equilibrium can be altered
by the action of various kinases able to phosphorylate residues within
UCR1 and the PDE4 catalytic unit [23–26,28–30,70,71]; through
mono-ubiquitination by the β-arrestin-sequestered E3 ligase, Mdm3
[32]; as a consequence of mutation of residues in UCR1 of PDE4D as
seen in acrodysostosis (e.g. Q164P and L166S in PDE4D5; [72]) and
when interacting with various partner proteins that sequester PDE4isoforms to underpin compartmentalised cAMP signalling [1]. Structural
studies of long and short isoforms, rather than just catalytic units, are
needed in order to comprehend differences consequent on monomer–
dimer inter-conversion.
Thus, the behaviour of PDE4 long forms is likely to be inherently
distinct from that of PDE4 short forms as a direct consequence of the
difference in quaternary structure, and doubtless this will contribute
to the distinct physiological roles fulﬁlled by different PDE4 isoforms.
Acknowledgements
GBB was supported by grant R01-GM58553 from the NIGMS, NIH,
USA; GSBwas supported byMRC grantMR/J007412/1; EKwas support-
ed by the Else Kroner-Fresenius Foundation (2013_A145) and the
German-Israeli Foundation for Scientiﬁc Research and Development
(I-1210-286.13/2012).
References
[1] M.D. Houslay, Trends Biochem. Sci. 35 (2010) 91–100.
[2] C. Lugnier, Pharmacol. Ther. 109 (2006) 366–398.
[3] D.H. Maurice, H. Ke, F. Ahmad, Y. Wang, J. Chung, V.C. Manganiello, Nat. Rev. Drug
Discov. 13 (2014) 290–314.
[4] M. Rogne, K. Tasken, Horm. Metab. Res. Horm. Metab. Res. 46 (12) (2014) 833–840.
http://dx.doi.org/10.1055/s-0034-1389955.
[5] M. Zaccolo, Br. J. Pharmacol. 158 (2009) 50–60.
[6] P. Skroblin, S. Grossmann, G. Schafer, W. Rosenthal, E. Klussmann, Int. Rev. Cell Mol.
Biol. 283 (2010) 235–330.
[7] J. Troger, M.C. Moutty, P. Skroblin, E. Klussmann, Br. J. Pharmacol. 166 (2012)
420–433.
[8] D. Willoughby, D.M. Cooper, Physiol. Rev. 87 (2007) 965–1010.
[9] M. Conti, J. Beavo, Annu. Rev. Biochem. 76 (2007) 481–511.
[10] M.D. Houslay, D.R. Adams, Biochem. J. 370 (2003) 1–18.
[11] T. Keravis, C. Lugnier, Curr. Pharm. Des. 16 (2010) 1114–1125.
[12] G.S. Baillie, FEBS J. 276 (2009) 1790–1799.
[13] H. Abrahamsen, G. Baillie, J. Ngai, T. Vang, K. Nika, A. Ruppelt, T. Mustelin, M. Zaccolo,
M. Houslay, K. Tasken, J. Immunol. 173 (2004) 4847–4858.
[14] M.D. Houslay, P. Schafer, K.Y. Zhang, Drug Discov. Today 10 (2005) 1503–1519.
[15] G. Bolger, T. Michaeli, T. Martins, T. St John, B. Steiner, L. Rodgers, M. Riggs, M.
Wigler, K. Ferguson, Mol. Cell. Biol. 13 (1993) 6558–6571.
[16] M. Conti, W. Richter, C. Mehats, G. Livera, J.Y. Park, C. Jin, J. Biol. Chem. 278 (2003)
5493–5496.
[17] M.D. Houslay, Prog. Nucleic Acid Res. Mol. Biol. 69 (2001) 249–315.
[18] M.D. Houslay, G.S. Baillie, D.H. Maurice, Circ. Res. 100 (2007) 950–966.
[19] M.J. Lynch, G.S. Baillie, A. Mohamed, X. Li, C. Maisonneuve, E. Klussmann, G. van
Heeke, M.D. Houslay, J. Biol. Chem. 280 (2005) 33178–33189.
[20] A.McCahill, T. McSorley, E. Huston, E.V. Hill, M.J. Lynch, I. Gall, G. Keryer, B. Lygren, K.
Tasken, G. van Heeke, M.D. Houslay, Cell. Signal. 17 (2005) 1158–1173.
[21] B. Serrels, E. Sandilands, A. Serrels, G. Baillie, M.D. Houslay, V.G. Brunton, M. Canel,
L.M. Machesky, K.I. Anderson, M.C. Frame, Curr. Biol. 20 (2010) 1086–1092.
[22] Y.Y. Sin, H.V. Edwards, X. Li, J.P. Day, F. Christian, A.J. Dunlop, D.R. Adams, M. Zaccolo,
M.D. Houslay, G.S. Baillie, J. Mol. Cell. Cardiol. 50 (2011) 872–883.
[23] C. Sette, M. Conti, J. Biol. Chem. 271 (1996) 16526–16534.
[24] C. Sette, S. Iona, M. Conti, J. Biol. Chem. 269 (1994) 9245–9252.
[25] R. Hoffmann, I.R. Wilkinson, J.F. McCallum, P. Engels, M.D. Houslay, Biochem. J. 333
(Pt 1) (1998) 139–149.
[26] S.J. MacKenzie, G.S. Baillie, I. McPhee, C. MacKenzie, R. Seamons, T. McSorley, J.
Millen, M.B. Beard, G. van Heeke, M.D. Houslay, Br. J. Pharmacol. 136 (2002)
421–433.
[27] G. Baillie, S.J. MacKenzie, M.D. Houslay, Mol. Pharmacol. 60 (2001) 1100–1111.
[28] G.S. Baillie, S.J. MacKenzie, I. McPhee, M.D. Houslay, Br. J. Pharmacol. 131 (2000)
811–819.
[29] R. Hoffmann, G.S. Baillie, S.J. MacKenzie, S.J. Yarwood, M.D. Houslay, EMBO J. 18
(1999) 893–903.
[30] C.L. Sheppard, L.C. Lee, E.V. Hill, D.J. Henderson, D.F. Anthony, D.M. Houslay, K.C.
Yalla, L.S. Cairns, A.J. Dunlop, G.S. Baillie, E. Huston, M.D. Houslay, Cell. Signal. 26
(2014) 1958–1974.
[31] K.F. MacKenzie, D.A. Wallace, E.V. Hill, D.F. Anthony, D.J. Henderson, D.M. Houslay,
J.S. Arthur, G.S. Baillie, M.D. Houslay, Biochem. J. 435 (2011) 755–769.
[32] X. Li, G.S. Baillie, M.D. Houslay, J. Biol. Chem. 284 (2009) 16170–16182.
[33] X. Li, S. Vadrevu, A. Dunlop, J. Day, N. Advant, J. Troeger, E. Klussmann, E. Jaffrey, R.T.
Hay, D.R. Adams, M.D. Houslay, G.S. Baillie, Biochem. J. 428 (2010) 55–65.
[34] N.J. Marianayagam, M. Sunde, J.M. Matthews, Trends Biochem. Sci. 29 (2004)
618–625.
[35] A. Banjac, M.O. Zimmermann, F.M. Boeckler, U. Kurz, A. Schultz, J.E. Schultz, Cell.
Signal. 24 (2012) 629–634.
[36] N. Handa, E. Mizohata, S. Kishishita, M. Toyama, S. Morita, T. Uchikubo-Kamo, R.
Akasaka, K. Omori, J. Kotera, T. Terada, M. Shirouzu, S. Yokoyama, J. Biol. Chem.
283 (2008) 19657–19664.
[37] Q. Huai, H. Wang,W. Zhang, R.W. Colman, H. Robinson, H. Ke, Proc. Natl. Acad. Sci. U.
S. A. 101 (2004) 9624–9629.
769G.B. Bolger et al. / Cellular Signalling 27 (2015) 756–769[38] T. Kovala, B.D. Sanwal, E.H. Ball, Biochemistry 36 (1997) 2968–2976.
[39] S.L. Matte, T.M. Laue, R.H. Cote, J. Biol. Chem. 287 (2012) 20111–20121.
[40] J. Pandit, M.D. Forman, K.F. Fennell, K.S. Dillman, F.S. Menniti, Proc. Natl. Acad. Sci. U.
S. A. 106 (2009) 18225–18230.
[41] W. Richter, M. Conti, J. Biol. Chem. 277 (2002) 40212–40221.
[42] W. Richter, M. Conti, J. Biol. Chem. 279 (2004) 30338–30348.
[43] M. Xie, B. Blackman, C. Scheitrum, D. Mika, E. Blanchard, T. Lei, M. Conti, W. Richter,
Biochem. J. 459 (2014) 539–550.
[44] K.G. Muradov, K.K. Boyd, S.E. Martinez, J.A. Beavo, N.O. Artemyev, J. Biol. Chem. 278
(2003) 10594–10601.
[45] S.E. Martinez, A.Y. Wu, N.A. Glavas, X.B. Tang, S. Turley, W.G. Hol, J.A. Beavo, Proc.
Natl. Acad. Sci. U. S. A. 99 (2002) 13260–13265.
[46] R. Zoraghi, E.P. Bessay, J.D. Corbin, S.H. Francis, J. Biol. Chem. 280 (2005)
12051–12063.
[47] M.D. Houslay, M. Sullivan, G.B. Bolger, Adv. Pharmacol. 44 (1998) 225–342.
[48] L.A. Johnston, S. Erdogan, Y.F. Cheung, M. Sullivan, R. Barber, M.J. Lynch, G.S. Baillie,
G. Van Heeke, D.R. Adams, E. Huston, M.D. Houslay, Biochem. J. 380 (2004) 371–384.
[49] M.B. Beard, A.E. Olsen, R.E. Jones, S. Erdogan, M.D. Houslay, G.B. Bolger, J. Biol. Chem.
275 (2000) 10349–10358.
[50] M.E. Lee, J. Markowitz, J.O. Lee, H. Lee, FEBS Lett. 530 (2002) 53–58.
[51] G.B. Bolger, S. Erdogan, R.E. Jones, K. Loughney, G. Scotland, R. Hoffmann, I.
Wilkinson, C. Farrell, M.D. Houslay, Biochem. J. 328 (Pt 2) (1997) 539–548.
[52] G.S. Baillie, D.R. Adams, N. Bhari, T.M. Houslay, S. Vadrevu, D. Meng, X. Li, A. Dunlop,
G. Milligan, G.B. Bolger, E. Klussmann, M.D. Houslay, Biochem. J. 404 (2007) 71–80.
[53] G.B. Bolger, G.S. Baillie, X. Li, M.J. Lynch, P. Herzyk, A. Mohamed, L.H. Mitchell, A.
McCahill, C. Hundsrucker, E. Klussmann, D.R. Adams, M.D. Houslay, Biochem. J.
398 (2006) 23–36.
[54] G.B. Bolger, A. McCahill, E. Huston, Y.F. Cheung, T. McSorley, G.S. Baillie, M.D.
Houslay, J. Biol. Chem. 278 (2003) 49230–49238.
[55] S.J. Perry, G.S. Baillie, T.A. Kohout, I. McPhee, M.M. Magiera, K.L. Ang, W.E. Miller, A.J.
McLean, M. Conti, M.D. Houslay, R.J. Lefkowitz, Science 298 (2002) 834–836.
[56] K.J. Smith, G.S. Baillie, E.I. Hyde, X. Li, T.M. Houslay, A. McCahill, A.J. Dunlop, G.B.
Bolger, E. Klussmann, D.R. Adams, M.D. Houslay, Cell. Signal. 19 (2007) 2612–2624.
[57] S.J. Yarwood, M.R. Steele, G. Scotland, M.D. Houslay, G.B. Bolger, J. Biol. Chem. 274
(1999) 14909–14917.[58] G.B. Bolger, A.H. Peden, M.R. Steele, C. MacKenzie, D.G. McEwan, D.A. Wallace, E.
Huston, G.S. Baillie, M.D. Houslay, J. Biol. Chem. 278 (2003) 33351–33363.
[59] D.M. Collins, H. Murdoch, A.J. Dunlop, E. Charych, G.S. Baillie, Q.Wang, F.W. Herberg,
N. Brandon, A. Prinz, M.D. Houslay, Cell. Signal. 20 (2008) 2356–2369.
[60] H. Murdoch, S. Mackie, D.M. Collins, E.V. Hill, G.B. Bolger, E. Klussmann, D.J. Porteous,
J.K. Millar, M.D. Houslay, J. Neurosci. 27 (2007) 9513–9524.
[61] H. Murdoch, S. Vadrevu, A. Prinz, A.J. Dunlop, E. Klussmann, G.B. Bolger, J.C. Norman,
M.D. Houslay, J. Cell Sci. 124 (2011) 2253–2266.
[62] C. Hundsrucker, P. Skroblin, F. Christian, H.M. Zenn, V. Popara, M. Joshi, J. Eichhorst,
B. Wiesner, F.W. Herberg, B. Reif, W. Rosenthal, E. Klussmann, J. Biol. Chem. 285
(2010) 5507–5521.
[63] U.K. Laemmli, Nature 227 (1970) 680–685.
[64] R.J. Marchmont, M.D. Houslay, Biochem. J. 187 (1980) 381–392.
[65] W.J. Thompson, M.M. Appleman, Biochemistry 10 (1971) 311–316.
[66] H. Wang, M.S. Peng, Y. Chen, J. Geng, H. Robinson, M.D. Houslay, J. Cai, H. Ke,
Biochem. J. 408 (2007) 193–201.
[67] C.P. Page, D. Spina, Curr. Opin. Pharmacol. 12 (2012) 275–286.
[68] A.B. Burgin, O.T. Magnusson, J. Singh, P. Witte, B.L. Staker, J.M. Bjornsson, M.
Thorsteinsdottir, S. Hrafnsdottir, T. Hagen, A.S. Kiselyov, L.J. Stewart, M.E. Gurney,
Nat. Biotechnol. 28 (2010) 63–70.
[69] M.D. Houslay, D.R. Adams, Nat. Biotechnol. 28 (2010) 38–40.
[70] S.J. MacKenzie, G.S. Baillie, I. McPhee, G.B. Bolger, M.D. Houslay, J. Biol. Chem. 275
(2000) 16609–16617.
[71] E.V. Hill, C.L. Sheppard, Y.F. Cheung, I. Gall, E. Krause, M.D. Houslay, Cell. Signal. 18
(2006) 2056–2069.
[72] T. Kaname, C.S. Ki, N. Niikawa, G.S. Baillie, J.P. Day, K. Yamamura, T. Ohta, G.
Nishimura, N. Mastuura, O.H. Kim, Y.B. Sohn, H.W. Kim, S.Y. Cho, A.R. Ko, J.Y. Lee,
H.W. Kim, S.H. Ryu, H. Rhee, K.S. Yang, K. Joo, J. Lee, C.H. Kim, K.H. Cho, D. Kim, K.
Yanagi, K. Naritomi, K. Yoshiura, T. Kondoh, E. Nii, H. Tonoki, M.D. Houslay, D.K.
Jin, Cell. Signal. 26 (2014) 2446–2459.
[73] G.L. Card, B.P. England, Y. Suzuki, D. Fong, B. Powell, B. Lee, C. Luu, M. Tabrizizad, S.
Gillette, P.N. Ibrahim, D.R. Artis, G. Bollag, M.V. Milburn, S.H. Kim, J. Schlessinger, K.Y.
Zhang, Structure 12 (2004) 2233–2247.
